L Fehrenbacher

First-line, single-agent Herceptin(R) (trastuzumab) in metastatic breast cancer. a preliminary report.

L. Harris, S. Shak, M. Cobleigh, 2001, European journal of cancer.

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.

J. Berlin, A. Jimeno, D. Aisner, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report.

L. Harris, D. Tripathy, S. Shak, 2001, European journal of cancer.